NB-9402 is Nura Bio's next-generation oral covalent allosteric SARM1 inhibitor in Phase 1a.
Competing Products
Nura Bio
Nura Bio: Pioneering neuroprotective medicines for revolutionary treatment of neurological diseases.
Nura Bio: Pioneering neuroprotective medicines for revolutionary treatment of neurological diseases.
Nura Bio, founded in 2018 by The Column Group and its scientific founders, is dedicated to revolutionizing the treatment of neurological diseases through innovative neuroprotective medicines. The company's core mission is to provide life-changing treatments that offer hope and potential cures for those diagnosed with neurological disorders. Nura Bio focuses on developing therapies that protect and preserve neural function, aiming to improve the quality of life for patients worldwide.
Notable figures associated with Nura Bio include its scientific founders and key investors from The Column Group, a prominent venture capital firm. The company has made significant strides in the field of neuroprotection, earning recognition for its groundbreaking research and development efforts. Nura Bio's impact is reflected in its commitment to advancing medical science and offering new therapeutic options for debilitating neurological conditions, positioning it as a leader in neuroprotective medicine.
Companies similar to Nura Bio include Asha Therapeutics, Neuraly, Bionure and Nido Biosciences.
Nura Bio was founded in 2018.
Nura Bio's headquarters is located in South San Francisco, CA, US.
Nura Bio's most recent funding round was for $73.8M (USD) in June 2026.
As of Jun 22, 2026, Nura Bio has disclosed funding of $146.8M (USD). Undisclosed round amounts are excluded.
Nura Bio has 22 employees as of Feb 4, 2024.
nidobio.com
